A Natural Bioactive Peptide from Pinctada fucata Pearls Can Be Used as a Potential Inhibitor of the Interaction between SARS-CoV-2 and ACE2 against COVID-19
Open Access
- 19 July 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (14) , 7902
Abstract
The frequent occurrence of viral infections poses a serious threat to human life. Identifying effective antiviral components is urgent. In China, pearls have been important traditional medicinal ingredients since ancient times, exhibiting various therapeutic properties, including detoxification properties. In this study, a peptide, KKCH, which acts against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was derived from Pinctada fucata pearls. Molecular docking showed that it bound to the same pocket of the SARS-CoV-2 S protein and cell surface target angiotensin-converting enzyme II (ACE2). The function of KKCH was analyzed through surface plasmon resonance (SPR), Enzyme-Linked Immunosorbent Assays, immunofluorescence, and simulation methods using the SARS-CoV-2 pseudovirus and live virus. The results showed that KKCH had a good affinity for ACE2 (KD = 6.24 × 10−7 M) and could inhibit the binding of the S1 protein to ACE2 via competitive binding. As a natural peptide, KKCH inhibited the binding of the SARS-CoV-2 S1 protein to the surface of human BEAS-2B and HEK293T cells. Moreover, viral experiments confirmed the antiviral activity of KKCH against both the SARS-CoV-2 spike pseudovirus and SARS-CoV-2 live virus, with half-maximal inhibitory concentration (IC50) values of 398.1 μM and 462.4 μM, respectively. This study provides new insights and potential avenues for the prevention and treatment of SARS-CoV-2 infections.Keywords
Funding Information
- National Natural Science Foundation of China (32072951)
This publication has 51 references indexed in Scilit:
- Small-molecule anti-COVID-19 drugs and a focus on China’s homegrown mindeudesivir (VV116)Frontiers of Medicine, 2023
- Risk of Death in Patients Hospitalized for COVID-19 vs Seasonal Influenza in Fall-Winter 2022-2023JAMA, 2023
- An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccinesHeliyon, 2023
- Virological characteristics of the SARS-CoV-2 Omicron BA.2 spikeCell, 2022
- Phytocompounds of Rheum emodi, Thymus serpyllum, and Artemisia annua Inhibit Spike Protein of SARS-CoV-2 Binding to ACE2 Receptor: In Silico ApproachCurrent Pharmacology Reports, 2021
- SARS-CoV-2: Targeted managements and vaccine developmentCytokine & Growth Factor Reviews, 2021
- Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interactionProtein & Cell, 2020
- Covid‐19 and kidney injury: Pathophysiology and molecular mechanismsReviews in Medical Virology, 2020
- In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19Computers in Biology and Medicine, 2020
- Chinese herbal compounds against SARS-CoV-2: Puerarin and quercetin impair the binding of viral S-protein to ACE2 receptorComputational and Structural Biotechnology Journal, 2020